Skip to main content

Are you Dr. Babiker?

Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.

  • Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
    You already have 49 invites waiting!
  • Read the latest clinical news, personalized to your specialty.

Claim this profile

Not you? Find your profile

  • Office

    4500 San Pablo Rd S
    Jacksonville, FL 32224
    Phone+1 480-301-8000

Summary

  • Dr. Hani Babiker, MD is a geriatrician in Jacksonville, Florida. He is currently licensed to practice medicine in Florida, Arizona, and New York. He is affiliated with Mayo Clinic Hospital in Florida.

Education & Training

  • University of Arizona College of Medicine-Tucson
    University of Arizona College of Medicine-TucsonFellowship, Hematology and Medical Oncology, 2012 - 2015
  • New York Presbyterian Hospital (Cornell Campus)
    New York Presbyterian Hospital (Cornell Campus)Fellowship, Geriatric Medicine (Internal Medicine), 2008 - 2009
  • New York-Presbyterian/Queens
    New York-Presbyterian/QueensResidency, Internal Medicine, 2006 - 2008
  • Comenius University
    Comenius UniversityClass of 2000

Certifications & Licensure

  • FL State Medical License
    FL State Medical License 2019 - 2026
  • AZ State Medical License
    AZ State Medical License 2009 - 2025
  • NY State Medical License
    NY State Medical License 2008 - 2014
  • OH State Medical License
    OH State Medical License 2008 - 2011
  • American Board of Internal Medicine Hematology
  • American Board of Internal Medicine Medical Oncology

Clinical Trials

Publications & Presentations

PubMed

Press Mentions

  • Improving Value in Pancreatic Cancer Care
    Improving Value in Pancreatic Cancer CareJanuary 4th, 2019
  • Spirita Oncology, LLC Initiates a Phase 1 Clinical Trial of the Anti-Cancer Agent E6201 in Patients with Central Nervous System Metastases from BRAF+ or MEK-Mutated Metastatic Melanoma
    Spirita Oncology, LLC Initiates a Phase 1 Clinical Trial of the Anti-Cancer Agent E6201 in Patients with Central Nervous System Metastases from BRAF+ or MEK-Mutated Metastatic MelanomaNovember 26th, 2018
  • Immunotherapy—Cancer's New Frontier
    Immunotherapy—Cancer's New FrontierApril 5th, 2018
  • Join now to see all

Professional Memberships